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Abstract
Retinoic acid (RA) treatment of embryonal carcinoma
cell line NTERA-2 clone D1 (NT2/D1) induces growth
arrest and terminal differentiation along the neuronal
pathway. In the present study, we provide a
functional link between RA and p27 function in the
control of neuronal differentiation in NT2/D1 cells.
We report that RA enhances p27 expression, which
results in increased association with cyclin E/cyclin-
dependent kinase 2 complexes and suppression of
their activity; however, antisense clones, which have
greatly reduced RA-dependent p27 inducibility (NT2-
p27AS), continue to synthesize DNA and are unable
to differentiate properly in response to RA as
determined by lack of neurite outgrowth and by the
failure to modify surface antigens. As to the
mechanism involved in RA-dependent p27 up-
regulation, our data support the concept that RA
reduces p27 protein degradation through the
ubiquitin/proteasome-dependent pathway. Taken
together, these findings demonstrate that in
embryonal carcinoma cells, p27 expression is




3 a biologically active metabolite of vitamin A, plays a
critical role during normal development and regulates growth
and/or differentiation in a variety of tumor cell lines (1). In
particular, strong evidence supports a role of RA in neuronal
development (2–4). EC cells represent a suitable model to
investigate the molecular mechanisms involved in RA signal-
ing. A clonal subline derived from the human EC NTERA-2
cell line (i.e., the NT2/D1 cells) exhibits the properties of
multipotent stem cells and differentiates into neurons on
treatment with RA (5). RA treatment of NT2/D1 cells results in
growth inhibition and neuronal differentiation, which can be
monitored by the expression of markers such as cytoskeletal
proteins and secretory or surface markers (i.e., A2B5; Refs.
6 and 7). RA-differentiated NT2/D1 cells resemble morpho-
logically primary neuronal cultures from rodents and elabo-
rate axons and dendrites (7, 8).
Terminal differentiation of cells requires withdrawal from
the cell cycle and induction of a novel program of gene
expression, which leads to the elaboration of a specialized
phenotype (9, 10). The factors that determine whether cells
continue to proliferate or arrest growth and differentiate op-
erate during the G1 phase of the cell cycle (11–13). Progres-
sion of a cell into S phase is dependent on the coordinated
activation of a small family of serine/threonine kinases, the
CDKs (14). CDKs play a crucial role in the G1 phase, and the
regulation of their function is critical for the commitment to
cell differentiation. The activity of CDKs is positively regu-
lated by association with activating subunits, the cyclins
(15–17), and is negatively regulated by a group of inhibitory
proteins called CKIs (18). Thus far, two classes of CKIs have
been identified: (a) the INK4 proteins that specifically inhibit
cyclin D-CDK4/CDK6; and (b) the Kip/Cip proteins that in-
hibit most cyclin-CDK complexes (19). The Kip/Cip family of
CKIs contains p21, p27, and p57 (20–22). Recent data in the
literature have pointed out that CKIs may be implicated in the
differentiation of various cell types (23–31). In particular, a
central role during neuronal differentiation has been pro-
posed for p27: p27 expression strictly correlates with the
differentiation grade of neuronal cells, both in vivo and in vitro
(32); differentiation of neuroblastoma cells by RA or thyroid
hormone is accompanied by p27 up-regulation; and p27
overexpression induces partial neuronal differentiation of
mouse neuroblastoma cells (33). Received 6/8/00; revised 8/30/00; accepted 8/31/00.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indi-
cate this fact.
1 Supported by grants from the Associazione Italiana Ricerca sul Cancro
and Progetto Finalizzato Biotecnologie of the CNR. A. B., P. B., M. L. M.,
and B. B. are supported by FIRC fellowships.
2 To whom requests for reprints should be addressed, at Oncologia Speri-
mentale E, Istituto Nazionale Tumori, via M. Semmola, 80131 Naples, Italy.
Phone: 081-5903549; Fax: 081-5903838; E-mail: gvigliet@tin.it.
3 The abbreviations used are: RA, retinoic acid; CDK, cyclin-dependent
kinase; CKI, CDK inhibitor; pRB, retinoblastoma protein; EGFP, eukaryotic
green fluorescent protein; CMV, cytomegalovirus; PI, propidium iodide;
EC, embryonal carcinoma; BrdUrd, bromodeoxyuridine; LLnL, N-acetyl-
leu-leu-nor leucinal; LLM, N-acetyl-leu-leu-methioninal.
517 Vol. 11, 517–526, October 2000 Cell Growth & DifferentiationIn this study we have investigated the role of p27 in the
process of neuronal differentiation induced by retinoids in EC
NT2/D1 cells. We provide straightforward evidence that up-
regulation of p27 is a key target of RA signaling in EC cells.
In fact, we report that RA enhances p27 expression and
induces increased association of p27 with cyclin E/CDK2
complexes and suppresses the activity of these complexes;
on the other hand, antisense clones, which have greatly
reduced RA-dependent p27 inducibility (NT2-p27AS), con-
tinue to synthesize DNA and are unable to differentiate prop-
erly in response to RA as determined by the failure to form
neurons or to modify surface antigens and by the lack of
neurite outgrowth. Finally, we provide data indicating that the
RA-dependent increase in p27 expression results from the
reduction in activity of the ubiquitin-proteasome pathway.
Results
Effects of RA on the Growth and Differentiation of
NT2/D1 Cells. Asynchronously proliferating NT2/D1 cells
were treated for 4, 7, and 15 days with 10 mM RA; labeled with
PI; and analyzed with FACScan. Typically, proliferating
NT2/D1 cells showed 44% of cells in the S-phase compart-
ment, whereas on RA treatment, cell growth was arrested,
and cells accumulated in G1 (26% of S-phase cells at 4 days
of treatment, 16% of S-phase cells at 7 days of treatment,
and 8% of S-phase cells at 15 days of treatment, respec-
tively). A representative experiment is reported in Fig. 1A.R A
treatment of NT2/D1 cells induces differentiation along the
neuronal pathway, with significant morphological changes,
outgrowth of neuritis, and modification of surface antigens,
as detected by indirect immunofluorescence. Undifferenti-
ated NT2/D1 cells are positive for the SSEA-3 antigen and
negative for the neuron-specific A2B5 antigen, whereas RA-
treated NT2/D1 cells become negative for SSEA-3 and pos-
itive for A2B5. Indirect immunofluorescence analysis of sur-
face antigens in exponentially growing NT2/D1 cells treated
for 7 days or 15 days with RA is shown in Fig. 1B. The
majority of unstimulated NT2/D1 cells express SSEA-3 but
not A2B5. Conversely, RA induced the loss of SSEA-3 ex-
pression and the appearance of A2B5 in most cells.
Changes in the Levels of Cyclins and CDKs during
RA-induced Differentiation. We investigated the expres-
sion of cell cycle regulators in RA-treated NT2/D1 cells. Cell
extracts were prepared from NT2/D1 cells exposed to 10 mM
RA for 1–7 days and analyzed by Western blot for the ex-
pression of cyclins, CDKs, and CKIs. No difference was
found in the expression of CDK1, CDK2, CDK4, CDK5,
CDK6, and CDK7 (Fig. 1C). Among the G1 cyclins, expres-
sion of cyclin D1 was decreased in RA-treated NT2/D1 cells
compared with proliferating NT2/D1 cells. RA did not modify
the expression of cyclin E, whereas the expression of cyclin
D3, which was expressed at a low level in proliferating cells,
increased steadily. The expression of the S-phase cyclin
(cyclin A) and the M-phase cyclin (cyclin B) were reduced at
4 and 5 days, respectively (Fig. 1D).
Expression of CKIs during RA-induced Differentiation.
Western blot analysis of the same cell extracts for the ex-
pression of CKIs demonstrated that RA induced an accumu-
lation of p27 protein at 2–3 days after the beginning of RA
treatment, with a peak at 7 days (Fig. 1E). p27 accumulation
preceded RA-induced G1 arrest, as indicated by the kinetics
of p27 expression relative to cell cycle distribution of NT2/D1
cells, thus providing experimental support to the idea that
p27 accumulation is crucial for RA-induced growth arrest of
NT2/D1 cells. Our findings that expression of p21 and p16
was increased at 7–10 days of RA treatment (Fig. 1E; data
not shown) suggest a possible role for these inhibitors only in
the late events. Conversely, RA did not affect p57 expression
Fig. 1. Effects of RA on cell cycle
and cell cycle-regulatory molecules in
NT2/D1 cells. A, asynchronously pro-
liferating NT2/D1 cells were treated for
4, 7, and 15 days with RA (10 mM) and
subsequently stained with PI; labeled
cells were analyzed with a FACScan
using the CELL-FIT program. A repre-
sentative experiment is shown. B, ex-
pression analysis of differentiative
markers in exponentially growing cells
and in RA-treated NT2/D1 cells (treat-
ed for 7 or 15 days, respectively). The
results represent the average of three
different experiments. C, effects ex-
erted by RA on the expression of
CDKs in NT2/D1 cells. D, effects ex-
erted by RA on the expression of cy-
clins in NT2/D1 cells. E, effects ex-
erted by RA on the expression of CKIs
in NT2/D1 cells. Red Ponceau staining
of the filters was performed in every
experiment to insure uniform protein
loading and integrity.
518 p27 in EC Cell Differentiation(data not shown). Such findings indicated a specific role for
p27 in growth inhibition and/or a differentiation commitment
of NT2/D1 cells induced by RA.
RA Fails to Induce p27 Expression in NT2-p27AS Cells.
To obtain direct experimental evidence that p27 represents a
necessary component of the cellular machinery that trans-
duces RA signaling in NT2/D1 cells, we generated NT2/D1
clones that stably expressed p27 cDNA in the antisense
orientation to block the synthesis of the endogenous protein.
NT2/D1 cells were transfected with pCMV-p27AS, and sev-
eral G418-resistant clones were collected. Using a Western
blot, we selected two independent NT2-p27AS clones that
showed the lowest levels of p27 protein in response to RA
(NT2-p27AS-Cl1 and NT2-p27AS-Cl2; Fig. 2A); however, at a
longer exposure time, p27 could also be detected in NT2-
p27AS, although at greatly reduced levels.
Conversely, no difference in the expression of other cell
cycle regulators (cyclin D3, cyclin E, CDK2, and CDK4, re-
spectively) was observed in NT2-p27AS cells (Fig. 2A). We
predicted that the increased levels of p27 seen in RA-treated
cells should be reflected in an increased amount of this
protein associated with cyclin/CDK complexes. As ex-
pected, we found significantly higher levels of p27 (5-fold)
associated with CDK2 in NT2/D1 cells treated with RA for 4
or 7 days compared with exponentially proliferating cells (Fig.
2B, top panel). Analysis of cyclin E-containing immunocom-
plexes in proliferating and RA-treated NT2/D1 cells showed
that RA increased the levels of p27 associated with cyclin E
by 3–4-fold (Fig. 2C, bottom panel). As a result of the in-
creased association of p27 with cyclin E/Cdk2 complexes
induced by RA, kinase activity associated with both cyclin E
and CDK2 was drastically reduced. Conversely, in NT2-
p27AS cells, the RA-dependent increase in the level of p27
associated with cyclin E or CDK2 was greatly reduced, re-
sulting in an increased level of kinase activity in the immu-
noprecipitates even after 7 days of RA treatment (Fig. 2, B
and C, respectively).
RA Inhibits pRB Phosphorylation in NT2/D1 Cells and
Suppresses pRB-phosphorylating Activity of CDKs. The
proteins of the pRB family (p105
RB, p107, and p130) play a
crucial role in growth arrest (34–37). pRB is underphospho-
rylated in G0-early G1 and becomes progressively phospho-
rylated by several G1 cyclin/CDK complexes during mid- to
late G1 (11, 38), a change accompanied by an inability to
block the G1 to S-phase transition. Western blot analysis of
cells committed to differentiate with RA treatment demon-
strated that the levels of p130 increased enormously after 7
days of treatment, whereas the levels of pRB were only
slightly augmented by RA (Fig. 3A). However, the hypophos-
phorylated form of p105 accumulated in response to RA
treatment; expression of p107 was detected in neither pro-
liferating nor RA-treated cells. Conversely, in NT2/D1-p27AS
cells, pRB phosphorylation was decreased, and accumula-
tion of p130 was completely prevented (Fig. 3).
p27 Is Necessary for RA-induced Growth Arrest of
NT2/D1 Cells. The two NT2-p27AS clones described above
were used to further investigate the molecular mechanism
whereby RA induces growth arrest and terminal differentia-
tion in EC cells. No difference was observed between
NT2/D1 cells and three different clones obtained using
pcDNA-3 vector transfection (NT2-CMV1.1, NT2-CMV1.5,
and NT2-CMV1.7); therefore, we will refer to all of them as
NT2/D1. NT2-p27AS-Cl1 and NT2-p27AS-Cl2 cells were an-
alyzed for their growth potential by two complementary
methodologies: (a) flow cytometry; and (b) measurement of
BrdUrd uptake. By flow cytometry, we found that after 15
days of RA treatment, NT2/D1 cells showed only 8% of cells
in S phase, whereas RA-treated NT2-p27AS cells showed
20% or 17% of S-phase cells, respectively, as shown in Fig.
3B. Similar results were obtained by measuring the rate of
BrdUrd incorporation: 49 6 6% of untreated NT2/D1 cells
Fig. 2. RA fails to induce p27 expression and activity in NT2-p27AS cells.
A, top panel, Western blot analysis of p27 in RA-treated NT2/D1 cells or
in two different NT2-p27AS clones (AS1 and AS2, respectively). Lower
panels, Western blot analysis of cyclin D3, CDK4, cyclin E, and CDK2 in
the same cell lysates. B, top panel, association of p27 with CDK2 in
NT2/D1 cells or in NT2-p27AS cells treated with RA for 4 or 7 days, as
indicated; middle panel, CDK2 level in the immunoprecipitates; bottom
panel, CDK2 activity on histone H1. C, top panel, association of p27 with
cyclin E in NT2/D1 cells or in NT2-p27AS treated with RA for 4 or 7 days,
as indicated; middle panel, cyclin E level in the immunoprecipitates;
bottom panel, cyclin E-associated activity on histone H1.
519 Cell Growth & Differentiationincorporated BrdUrd if labeled for 1 h, but only 12 6 3% or
4 6 1% of NT2/D1 cells incorporated BrdUrd if treated with
RA for 7 days or 15 days, respectively (Fig. 3C). When cells
depleted of p27 (NT2-p27AS-Cl1 and NT2-p27AS-Cl2) were
analyzed, we found that on average, 25–28% and 21–24% of
cells continued to incorporate BrdUrd after 7 or 15 days of
RA treatment, respectively. These results demonstrated that
p27 expression is required for G1 arrest induced by RA in
NT2/D1 cells.
p27 Is Necessary for RA-induced Differentiation of
NT2/D1 Cells. Subsequently, we investigated whether RA
was able to induce morphological or biochemical differenti-
ation in the absence of p27 expression. Cell morphology was
investigated by staining polymerized actin with phalloidin.
NT2/D1 cells are small polygonal cells. On treatment with RA,
the cells become flat and more adherent to the plate, with
neuritis extending from the cellular body. NT2-p27AS cells
show a morphology similar to that of NT2/D1 cells in the
absence of differentiative stimuli. However, when the mor-
phology of NT2-p27AS cells was analyzed after 15–21 days
of RA treatment, a different result was obtained:. RA-treated
NT2-p27AS cells were generally similar to untreated parental
NT2/D1 cells and clearly failed to achieve full terminal differ-
entiation because the outgrowth of neuritis was prevented by
depletion of p27 (Fig. 4, A and B).
Differentiation of NT2/D1 cells was also investigated by
indirect immunofluorescence analysis of surface markers.
Cells were plated onto slides, treated for 21 days with RA,
and processed for antigen analysis by indirect immunofluo-
rescence. Neuronal differentiation of NT2/D1 cells induced
by RA is reflected by significant modification of surface an-
tigens. Undifferentiated NT2/D1 cells have a SSEA-3
1/
A2B5
2 antigenic profile; conversely, RA-treated NT2/D1
cells lose SSEA-3 expression and acquire the expression of
A2B5 antigen (Fig. 4C, left column). In contrast with untrans-
fected or vector-transfected cells, RA treatment of NT2-
p27AS cells failed to induce down-regulation of SSEA-3
expression and up-regulation of A2B5 expression: the anti-
genic profile of NT2-p27AS cells remained SSEA-3
1/A2B5
2
(Fig. 4C, right column). Statistical analysis of RA-dependent
differentiation of NT2/D1 or NT2-p27AS cells is shown in
Fig. 4D.
RA Induced a Block in the Ubiquitin-dependent Prote-
olysis of p27. The expression of p27 is essentially regulated
at the posttranscriptional level. Two mechanisms in particu-
lar have been proposed: (a) modulation of mRNA translation
efficiency (29); and (b) regulation of protein turnover by a
pathway that involves ubiquitination-dependent proteolytic
degradation through the 26S proteasome (39). Ubiquitination
of p27 and subsequent degradation require the phosphoryl-
ation of a key regulatory residue, threonine 187, by the cyclin
E/CDK2 complex (40, 41). In this study, we sought to deter-
mine the mechanism whereby RA regulated p27 expression
in NT2/D1 cells. Northern blot analysis demonstrated that RA
only slightly increases in the steady-state levels of p27
mRNA (Fig. 5A), suggesting that most p27 accumulation
after RA treatment was due to a posttranscriptional mecha-
nism. To determine whether the proteasome pathway was
involved in the degradation of p27 protein in NT2/D1 cells,
cells were treated with two highly specific proteasome inhib-
itors (the peptide aldheyde LLnL and the inhibitor MG132).
As a control, we used the structurally related calpain I inhib-
itor LLM, which does not act on the 26S proteasome (42).
NT2/D1 cells were treated for 6–12 h with 50 mM LLnL or LLM
and 20 mM MG132 and analyzed by Western blot for p27 (Fig.
5B). As compared with untreated cells, DMSO-treated cells,
or cells treated with the same dose of LLM (Fig. 5B, Lanes
1–3, respectively), LLnL treatment resulted in a 3.5-fold in-
Fig. 3. p27 is necessary for RA-induced growth arrest of NT2/D1 cells. A,
Western blot analysis of pRB and p130 in control NT2/D1 or NT2-p27AS
cells treated with RA for the indicated times. pRB and phosphorylated
pRB (ppRb) are indicated. Red Ponceau staining of the filters was per-
formed in every experiment to insure uniform protein loading and integrity.
B, flow cytometry analysis of NT2/D1 or NT2-p27AS cells after treatment
with RA for 0 and 15 days. C, BrdUrd incorporation rate of NT2/D1 or
NT2-p27AS cells after treatment with RA for 0, 7, and 15 days.
520 p27 in EC Cell Differentiationcrease in the p27 level (Fig. 5B, Lane 4), suggesting that in
cycling NT2/D1 cells, the proteasome-dependent pathway
takes part in p27 turnover. The same results were obtained
with MG132 (Fig. 5B, Lane 5). RA treatment induced the
accumulation of a higher molecular weight monoubiquiti-
nated p27. As a complementary approach, we evaluated the
ability of extracts from NT2/D1 cells cultured in the absence
or presence of RA to degrade recombinant p27 in vitro.
Proteasome extracts prepared from undifferentiated cells
and from NT2/D1 cells treated for 3 or 6 days with RA were
incubated at 37°C with 1 mg of recombinant p27, followed by
Western blotting for p27. We found that the extracts derived
from cycling NT2/D1 cells degraded exogenous p27 more
rapidly than extracts derived cells treated with RA, which
suggested that most of RA-induced p27 up-regulation may
result from increased p27 protein stability due to the inhibi-
tion of p27 degradation. In summary, both in vivo (Fig. 5B)
and in vitro (Fig. 5C) experiments indicated that the pro-
teasome pathway was involved in the rapid posttransla-
tional turnover of p27 protein in cycling NT2/D1 cells.
Moreover, the results obtained with cell extracts in vitro
suggested that RA decreased the turnover of p27 protein.
Transfection of FLAG-tagged p27 into NT2/D1 cells in the
presence or absence of RA, followed by Western blot
analysis with monoclonal anti-p27 antibodies, demon-
strated that p27 protein is 2–3-fold less stable in untreated
NT2/D1 cells than in NT2/D1 cells treated with RA for 8
days (compare Lanes 1 and 3 in Fig. 6A). The transfection
of FLAG-p27 along with a plasmid encoding ubiquitin did
not modify the level of FLAG-p27 in cycling cells or in
RA-treated cells (compare Lanes 1and 2 and Lanes 3 and
4 in Fig. 6A), suggesting that ubiquitin is not rate-limiting
for the reduced degradation rate of p27 observed in RA-
treated cells.
Fig. 4. p27 is necessary for RA-induced differentiation of NT2/D1 cells. A,
NT2/D1 or NT2-p27AS cells were seeded onto coverslips, treated with 10
mM RA for 15 days, and subsequently stained with phalloidin to provide
evidence of cell morphology. B, neuron formation is impaired in NT2-p27AS
cells. The number of neurons in each case was calculated by light micros-
copy observation by considering neurons to be the cells that have neuritis
at least twice as long as the cellular bodies. C, differentiation of NT2/D1 cells
by RA is impaired if RA-dependent p27 expression is prevented by anti-
sense methodology. NT2/D1 or NT2-p27AS cells were seeded onto cover-
slips, treated with 10 mM RA for 15 days, and subsequently stained with
anti-SSEA-3 or anti-A2B5 antibodies. D, statistical analysis of SSEA-3 and
A2B5 positivity in NT2/D1, NT2-p27AS-Cl1 and NT2/p27AS-Cl2 cells.
521 Cell Growth & DifferentiationSubsequently, we determined whether threonine 187
phosphorylation and consequent ubiquitination were in-
volved in the regulation of p27 protein in NT2/D1 cells. As
suggested recently by Montagnoli et al. (40), degradation of
p27 through the proteasome pathway requires threonine 187
phosphorylation-dependent ubiquitination. To determine
whether p27 ubiquitination in cycling NT2/D1 cells was de-
pendent on threonine 187, NT2/D1 cells were transfected
with FLAG-tagged wild-type p27 or with mutant FLAG-
p27187TA in the absence or presence of a plasmid carrying
hemagglutinin-tagged ubiquitin. Western blot analysis of co-
transfected EGFP was used to normalize transfection effi-
ciency. Cell extracts were prepared, and the appropriate
amount of proteins, normalized by the level of transfection
efficiency (approximately 400 mg), was immunoprecipitated
with anti-FLAG antibodies. Immunoprecipitated proteins
were subsequently separated by 12.5% SDS-PAGE and an-
alyzed with monoclonal anti-p27 antibodies (Fig. 6B). When
transfected with FLAG-p27 together with a plasmid encoding
ubiquitin, prolonged exposition of the immunoblots also re-
vealed the occurrence of a series of p27-related bands with
higher molecular mass, the most prominent of which was of
approximately 40 kDa (compare Lanes 7 and 8 in Fig. 6B).
The 40-kDa band has been described as a monoubiquiti-
nated form of p27 (39, 43). Ubiquitinated p27 markedly ac-
cumulated in the presence of proteasome inhibitors (LLnL or
MG132; compare Lanes 7 and 9 or Lanes 8 and 10 in Fig. 6B),
which indicates that in NT2/D1 cells, monoubiquitinated p27
is rapidly degraded unless proteasome activity is inhibited.
Conversely, the mutant FLAG-p27187TA could not be ubiq-
uitinated. These results demonstrate that in NT2/D1 cells,
p27 degradation occurs by phosphorylation of p27 on thre-
onine 187, ubiquitination, and rapid destruction of the ubiq-
uitinated protein through the 26S proteasome.
Finally, we investigated the effects exerted by RA treat-
ment on the rate of p27 ubiquitination. NT2/D1 cells were
treated with DMSO or RA for 4 days, transfected with FLAG-
p27, and incubated for 2 additional days with DMSO or RA.
The proteasome inhibitor MG132 (20 mM) was added 12 h
before cells were collected. Transfection efficiency was de-
termined by immunoblot determination of cotransfected
EGFP. Proteins were analyzed by Western blot with anti-
FLAG antibodies. Unexpectedly, as shown in Fig. 6C,R A
treatment increased the level of ubiquitinated FLAG-p27 as
compared with DMSO-treated cells (compare Lanes 2 and 3
in Fig. 6C). This observation indicates that in NT2/D1 cells,
RA does not reduce the ubiquitination of p27 protein but that
it does reduce the turnover of ubiquitinated p27, at least at 6
days.
Discussion
In this study, we demonstrate the involvement of the CKI p27
in the growth arrest and neuronal differentiation induced by
RA in EC cells. Growth arrest of EC NT2/D1 cells induced by
RA is preceded by early accumulation of p27 but not of other
CKIs. More direct evidence that causally links RA-dependent
growth arrest and p27 protein accumulation is provided by
antisense experiments. Inhibition of RA-induced p27 up-
regulation in stably transfected p27AS antisense cells results
in failure to block cell growth and to progress along the
differentiative pathway properly, even after 15 days of RA
treatment. In fact, in contrast to NT2/D1 cells, most of which
accumulate in the G1 compartment after 7–15 days of RA
treatment, we have observed that more than 20% of NT2-
p27AS cells are in the S-phase compartment and continue to
proliferate in response to RA. Also, the neuronal differentia-
tion program triggered by RA is severely impaired if RA-
dependent p27 up-regulation is prevented. In fact, NT2-
p27AS cells did not show any morphological sign of neuronal
differentiation, which is usually observed in RA-treated
NT2/D1 cells. Unlike NT2/D1 cells, which develop neuritis
after 2–3 weeks of RA treatment, NT2-p27AS cells main-
tained a polygonal shape and did not develop neuronal pro-
cesses even after prolonged exposure to RA. The results
obtained from the analysis of differentiation-specific markers
were consistent with morphological data. Unlike control
cells, NT2-p27AS cells fail to down-regulate expression of
Fig. 5. RA induces p27 up-regulation by reducing the proteasome-de-
pendent p27 degradation rate. A, Top panel, Western blot analysis of p27
protein level in exponentially proliferating cells (Lane 1) or RA-treated cells
(Lanes 2–7). Red Ponceau staining of the filters was performed in every
experiment to insure uniform protein loading and integrity. Middle and
bottom panels, Northern blot analysis of p27 in exponentially proliferating
(Lane 1) or RA-treated (Lanes 2–7) cells; p27 (middle panel) and glycer-
aldehyde-3-phosphate dehydrogenase (bottom panel) were used to nor-
malize the amount of RNA loaded. B, effects of LLM, LLnL, and MG132 on
the stability of p27 protein. Western blot analysis of p27 protein level in
exponentially proliferating cells (Lane 1) and in DMSO (Lane 2)-, LLM (Lane
3)-, LLnL (Lane 4)-, and MG132-treated cells (Lane 5). C, rate of p27
degradation in extracts from proliferating (2) and RA-treated (3 and 6
days, respectively) NT2/D1 cells. One mg of recombinant p27 was incu-
bated at 37°C with 100 mg of proteasome extracts for 0, 6, or 12 h,
respectively, and the subsequent Western blotting analysis revealed the
amount of intact p27 protein.
522 p27 in EC Cell DifferentiationSSEA-3 and up-regulate expression of the neuron-specific
antigen A2B5 in response to RA.
Retinoids play an important role in neuronal differentiation.
However, the molecular basis of RA-dependent signaling has
remained elusive thus far. Recently, p27 has been associ-
ated with RA-induced growth arrest in SMS-KCNR and
LAN-5 human neuroblastoma cell lines, although no func-
tional implications were reported in those studies (43, 44).
Conversely, our results indicate that p27 up-regulation is
required for terminal differentiation signaled by RA. Interest-
ingly, it seems that RA signals preferentially through p27 in
cells that differentiate along the neuronal pathway (neuro-
blastomas and ECs) but not in breast cancer cells (MCF-7;
Ref. 45). The results reported here allowed us to propose that
p27 represents a key regulator of RA signaling in NT2/D1
cells. Accordingly, a previous work from our laboratory
showed that in these EC cells, p27 functions at a critical
switch point where growth arrest is followed by differentia-
tion (46). Recently, Spinella et al. (47) have proposed that
down-regulation of cyclin D1 may play a role in RA-depend-
ent growth arrest and differentiation of NT2/D1 cells. In fact,
constitutive expression of cyclin D1 protein blocked RA-
mediated growth arrest and differentiation; moreover, RA
receptor g-deficient NT2/D1 cells (NT2/D1-R1) that do not
arrest growth in response to RA showed persistent cyclin D1
overexpression but normal p27 inducibility. These results
can be reconciled with the central role of p27 in RA-depend-
ent growth arrest and differentiation of NT2/D1 cells that
emerges in this study, if overexpressed cyclin D1 in NT2/D1
cells would not directly activate CDK4–6 but act indirectly by
titolating p27 away from cyclinE/CDK2, as is proposed to
occur in the titration model (48–50).
The mechanism whereby p27 inhibits proliferation in
NT2/D1 cells likely involves binding to CDK2-containing
complexes with consequent inhibition of the kinase. The
inhibition of such G1 CDK activities results in the accumula-
tion of pRB and p130 in their hypophosphorylated, active
state, which suggests that the proteins of the retinoblastoma
family represent the final end point of RA signaling. Accord-
ingly, accumulation and dephosphorylation of pRB and p130
did not occur in NT2-p27AS cells. It is likely that in NT2/D1
cells, RA blocks degradation of p130 by inhibiting CDK-
dependent phosphorylation; conversely, in NT2-p27AS cells,
RA is not able to prevent p130 degradation because it fails to
suppress CDK activity. This observation is consistent with
the notion that in cycling cells, p130 is degraded through a
phosphorylation-dependent mechanism, and its accumula-
tion occurs in cells that have definitively left cell cycle and
arrest in G0 (38).
In cycling NT2/D1 cells, p27 levels are regulated posttrans-
lationally. The generally accepted model requires p27 phos-
phorylation by cyclin E/CDK2 on threonine 187, which allows
recognition by proteins that target p27 for ubiquitination and
degradation (40, 51). Our results indicate that in undifferen-
tiated NT2/D1 cells, the ubiquitin/proteasome pathway is
involved in the degradation of p27 protein. The level of p27
protein is markedly up-regulated if NT2/D1 cells are treated
with proteasome inhibitors (LLnL and MG132); proteasome-
containing extracts derived from cycling NT2/D1 cells show
a high degradation rate of exogenous recombinant p27 pro-
tein.
The data reported in this work further indicate that in
cycling NT2/D1 cells, phosphorylation and subsequent ubiq-
uitination of p27 are involved in p27 turnover. In fact, when
Fig. 6. A, Western blot analysis of the steady-state level of FLAG-tagged p27 in solvent or in NT2/D1 cells treated with RA for 6 days. Lane 1,
DMSO-treated cells transfected with FLAG-p27; Lane 2, DMSO-treated cells transfected with FLAG-p27 and ubiquitin; Lane 3, cells treated with RA for 6
days and transfected with FLAG-p27; Lane 4, cells treated with RA for 6 days and transfected with FLAG-p27 and ubiquitin; pEGFP was used to normalize
for transfection efficiency in all experiments. B, effects of ubiquitin and MG132 on the ubiquitination of wild-type p27 or FLAG-p27T187A mutant. Lane 1
(C), untransfected cells. Lanes 2–5, cells transfected with FLAG- p27T187A in the presence or absence of a plasmid encoding ubiquitin and the proteasome
inhibitor MG132, as indicated. Lanes 6–10, cells transfected with wild-type FLAG-p27 in the presence or absence of a plasmid encoding ubiquitin and the
proteasome inhibitor MG132, as indicated. All lysates were immunoprecipitated with M2 anti-Flag antibodies (except for those in Lane 6, for which control
normal mouse serum was used) and then probed by Western blot with anti-p27 antibodies. Bottom panel, EGFP expression as a control of transfection
efficiency. C, effects of RA on p27 ubiquitination. Cells were treated with DMSO or RA for 4 days and then transfected with FLAG-p27. After transfection,
DMSO (Lane 1), MG132 (Lane 2), or RA (Lane 3) was added. Proteins were extracted in the presence of 5 mM N-ethyl-maleimide, and p27 ubiquitination
was probed with anti-p27 antibodies.
523 Cell Growth & Differentiationcycling NT2/D1 cells are transfected with FLAG-p27 together
with a plasmid encoding ubiquitin, prolonged exposition of
immunoblots revealed the occurrence of ubiquitinated p27-
related bands with higher molecular mass (.40 kDa; Refs. 39
and 43). Ubiquitinated p27 accumulates in the presence of
proteasome inhibitors (LLnL and MG132), indicating that
ubiquitinated p27 is rapidly degraded in untreated NT2/D1
cells, unless proteasome activity is inhibited. Our results also
indicate that phosphorylation of threonine 187 is necessary
for p27 ubiquitination and degradation because FLAG-
p27187TA, a mutant in which the residue threonine 187 has
been replaced by alanine, cannot be efficiently ubiquitinated.
RA regulates p27 expression by protein stabilization. RA did
not induce consistent modification of p27 mRNA levels; pro-
teasome-containing extracts derived from RA-treated cells
show a lower degradation rate of exogenous recombinant
p27 protein compared with extracts from cycling cells; fi-
nally, FLAG-p27 protein is more stable when transiently
transfected in RA-treated NT2/D1 cells than in cycling cells.
However, RA treatment does not appear to reduce ubiquiti-
nation of p27; instead, it reduces the degradation of the
ubiquitinated forms.
In conclusion, we demonstrate that p27 represents a key
factor in the RA-dependent pathways that regulate growth
and terminal differentiation of EC cells. However, additional
studies are necessary to clarify the molecular mechanisms
whereby RA modulates p27 removal by the 26S proteasome.
Materials and Methods
Cell Culture and Treatment. The NT2/D1 cell line was
grown in DMEM (Sigma Inc.) supplemented with 10% heat-
inactivated FCS (Sigma), 4 mM glutamine (Life Technologies,
Inc.), 100 units/ml penicillin, and 10 ng/ml streptomycin (Life
Technologies, Inc.). RA (Sigma) was solubilized in DMSO and
used at a final concentration of 10 mM. Differentiation of the
NT2/D1 cell line was performed as described previously (46,
52). Cells were plated at a dilution of 1.1 3 10
6 cells/10-mm
culture dish and exposed to 10 mM RA or DMSO for 0, 1, 2,
3, 4, 5, and 7 days. After 7 days in the presence of RA or
DMSO, cells were plated at a low dilution and cultured for
1–2 additional weeks to obtain the fully differentiated phe-
notype.
Flow Cytometric Analysis. NT2/D1 cells were analyzed
for DNA content and expression of cell surface antigens as
described previously (46). Cells were collected and washed
in PBS. DNA was stained with PI (50 mg/ml) and analyzed
with a FACScan flow cytometer (Becton Dickinson, San
Jose, CA) interfaced with a Hewlett Packard (Palo Alto, CA)
computer. Cell cycle analysis was performed by using the
CELL-FIT program (Becton Dickinson; Ref. 46). Detection of
SSEA-3 or A2B5 monoclonal antibodies was performed as
described previously (46).
RNA Extraction, Northern Blotting, and Hybridization.
Total cellular RNA was isolated from cultured cell lines as
described previously (53). Northern blots were performed as
described using nylon Hybond-N membranes (Amersham
Pharmacia Biotech) according to the manufacturer’s instruc-
tions (54). All cDNA probes were radiolabeled with a random
prime synthesis kit (Amersham Pharmacia Biotech). The
probes used in this study are the coding region of human p27
cDNA and the coding region of the human glyceraldehyde-
3-phosphate dehydrogenase cDNA obtained by RT-PCR.
Protein Extraction, Western Blotting, and Antibodies.
Cells were scraped in ice-cold PBS and subsequently lysed
in ice-cold NP40 lysis buffer [0.5% NP40, 50 mM HEPES (pH
7), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.5 mM Na3VO4,
0.5 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, and
5 mg/ml leupeptin]. In some experiments, 5 mM N-ethyl-
maleimide (Sigma) was added to the lysis buffer to preserve
ubiquitin-conjugated proteins. Proteins were analyzed on
polyacrylamide gel, transferred to nitrocellulose membranes
(Hybond-C; Amersham), incubated with specific primary an-
tibodies, and visualized by using enhanced chemilumines-
cence (Amersham). The antibodies used in this work were
obtained from Santa Cruz Biotechnology (anti-p27, C-19;
anti-cyclin D3, C16; anti-cyclin D1, HD11; anti-cyclin D2,
C-17; anti-cyclin D3, C16; p130, C20), Oncogene Science
(anti-cyclin A, AB-2; anti-p21, AB-1), PharMingen (anti-p16,
anti-cyclin B1, anti-cyclin D1, anti-cyclin E, HE12; anti-
CDK1, A17; anti-pRB, G3-245; anti-cyclin A, BF638;
anti-cyclin E, HE67; anti-CDK2 and anti-CDK4), Sigma (anti-
FLAG, M2) and Transduction Laboratories (anti-p27,
anti-CDK2).
Immunoprecipitation and Kinase Assay. NT2/D1cells
were lysed in NP40 lysis buffer. Proteins (400 mg) were
immunoprecipitated with 1–2 mg of the indicated antibodies
f o r2ha t4 ° Ca n dcollected on protein A/G-Sepharose (Santa
Cruz Biotechnology). Nine-tenths of the immunoprecipitated
proteins were resolved on SDS-polyacrylamide gels, trans-
ferred to nitrocellulose filters, and incubated with primary
antibodies as described above. One-tenth of the immuno-
precipitates was resuspended in kinase buffer [20 mM 4-mor-
pholinepropanesulfonic acid (pH 7.2), 25 mM b-glycerol
phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM
DTT, 7.5 mM MgCl2,5 0m M ATP, 1 mCi of [g-
32P]ATP and 5
mg of histone H1] for cyclin E- or CDK2-associated kinase
activity or in 1 mg of glutathione S-transferase-pRB 769
(Santa Cruz Biotechnology) for cyclin D3- or CDK4-associ-
ated activity and incubated for 15 min at 30°C. Incorporation
of radioactive phosphate was determined by using a phos-
phorimager (GS-525 Bio-Rad) interfaced with a Hewlett
Packard computer after SDS-PAGE.
Plasmids and Cell Transfections. The plasmids encod-
ing human p27 have been described previously (46, 48). To
obtain stable transfectants in which p27 expression was
down-regulated, NT2/D1 cells were transfected with
pcDNA-3 or its derivate pCMV-p27AS using N-[1-(2,3-dio-
leoyloxyl)propyl]-N,N,N-trimethylammoniummethyl sulfate li-
posomal transfection reagents (Roche Biochemical) accord-
ing to manufacturer’s instructions. After G418 (Life
Technologies, Inc.) selection, several resistant clones were
picked and analyzed for p27 expression. Among others, two
clones positives for p27AS (clones 1 and 2) were used for all
described experiments. NT2-CMV clones showed no modi-
fication in p27 expression, and the following analyses were
conducted using clones NT2-CMV1.1, NT2-CMV1.5, and
NT2-CMV1.7.
524 p27 in EC Cell DifferentiationImmunofluorescence Analysis. Detection of BrdUrd and
surface antigens was carried out essentially as described
previously (46, 52). Hoechst staining of cell nuclei was per-
formed in each experiment. Fluorescence was analyzed on
an epifluorescence microscope Axioplan 2 (Zeiss) able to
discriminate between Texas red and Hoechst staining.
In Vitro Degradation of p27 Protein. In vitro degradation
of p27 protein was carried out essentially as described pre-
viously (55). Briefly, NT2/D1 cells were grown for 3 or 7 days
in the presence of 10 mM RA or solvent, collected, and frozen
immediately at 280°C. Protein extracts were prepared as
described previously (55) and incubated (100 mg) with 1 mgo f
recombinant His-tagged p27 protein. After the indicated
times, reactions were stopped by adding 1 volume of 23
Laemmli buffer and loaded onto 12.5% polyacrylamide gel.
p27 protein was visualized by using an anti-p27 monoclonal
antibody. Quantification of the p27 level was performed by
subsequent scanning of films.
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